Many biological mechanisms depend on a state of signaling homeostasis maintained by the appropriate integration of synergistic and antagonistic signaling pathways. Accordingly, the symptoms of numerous diseases result from genetic mutations that disrupt this homeostasis. The relationships between signaling pathways suggest avenues through which homeostasis can be restored and disease symptoms subsequently alleviated. Specifically, disruptions caused by a loss-of-function mutation in a particular pathway may be compensated by concomitant perturbations in an antagonistic pathway. We use here a prediction-based approach to identify genetic interactions that allow such pathway relationships to be mapped. In particular, we identified genetic interactors for the Rab-specific guanine-nucleotide dissociation inhibitor
gdi-1 in the nematode Caenorhabditis elegans.
gdi-1 is a close homolog of GDI1, a gene encoding a major cell signaling protein associated with non-syndromic forms of mental retardation in human (aGDI). Our genome-wide approach predicts over 800,000 novel genetic interactions in C. elegans with an estimated accuracy ranging from 42% to 67%. Our novel methodology of data integration using the guilt-by-association principle is likely responsible for the improved genome coverage and accuracy of the predicted interactions when compared to previous studies. By validating a subset of interactions predicted for
gdi-1, we confirmed five novel genetic interactors for this gene. More specifically, we demonstrated that
gdi-1activity is antagonistic with phosphorylated myosin-light chain and
dyb-1 activities, during gonad morphogenesis and ovulation in C. elegans.
dyb-1 encodes the C. elegans ortholog of dystrobrevin, a component of the dystroglycan complex associated with Duchenne Muscular Dystrophy (DMD). We showed that
gdi-1 antagonism with
dyb-1 is conserved at neuromuscular junctions, where
gdi-1(RNAi) suppresses
dyb-1-associated muscle degeneration. Our data suggest that GDI1 would be a potent therapeutic target for DMD. In addition, it is of interest to investigate whether
dyb-1 would be a potent therapeutic target for cognitive disabilities associated with mutations in GDI1. In conclusion, we have shown that our methodology has the potential to streamline the therapy development process for monogenic disorders that involve genes and signaling pathways conserved between human and C. elegans.